US2014255982A1PendingUtilityA1

Method of cancer diagnosis using the analysis of isotopes

Assignee: CHOI WON CHEOLPriority: Aug 27, 2007Filed: May 20, 2014Published: Sep 11, 2014
Est. expiryAug 27, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Won Cheol Choi
G01N 33/84H01J 49/0027C12Q 1/04G01N 33/49G01N 33/57525G01N 33/57515G01N 33/57505G01N 33/5753G01N 33/5752G01N 33/5758G01N 33/575G01N 33/53A61P 39/06G01N 33/48G01N 33/57484
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is a method of diagnosing cancer on the basis of the quantitative analysis of blood or tissue isotopes, for example, such as 36 S or 40 K. The method can accurately diagnose cancer in a patient even when it is too small for current conventional technology to diagnose.

Claims

exact text as granted — not AI-modified
1 . A method of diagnosing cancer in a patient, comprising
 (a) measuring the level of isotope  40 K in a blood sample or a tissue sample of the patient by using a double-focus type mass spectrophotometer;   (b) measuring the level of Deuterium  2 D or  18 O in a blood sample or a tissue sample of the patient using a double-focus type mass spectrophotometer;   (c) diagnosing cancer in the patient if (i)  40 K is not detected and (ii) if the level of the  2 D or  18 O isotope is greater than the level of a normal standard for the  2 D or  18 O isotope.   
     
     
         2 . The method according to  claim 1 , wherein the method comprises measuring the level of deuterium  2 D in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 1.2 times increased level of  2 D is detected in the blood sample or tissue sample of the patient compared to a normal standard for  2 D isotope, or the method comprises measuring the level of  18 O in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 1.4 times increased level of  18 O is detected in the blood sample or tissue sample of the patient compared to a normal standard for  18 O isotope. 
     
     
         3 . The method according to  claim 1 , wherein the method further comprises measuring the level of at least one from the group consisting of sulfur isotopes, magnesium isotopes, silicon isotopes, calcium isotopes and iron isotopes in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if an increased level of at least one from the group consisting of sulfur isotopes, magnesium isotopes, silicon isotopes, calcium isotopes and iron isotopes is detected in the blood sample or tissue sample of the patient compared to a normal standard for the isotope. 
     
     
         4 . The method according to  claim 3 , wherein the method comprises measuring the level of sulfur isotope  33 S or  34 S in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 1.3 times increased level of  33 S or  34 S is detected in the blood sample or tissue sample of the patient compared to a normal standard for  33 S or  34 S. 
     
     
         5 . The method according to  claim 3 , wherein the method comprises measuring the level of  26 Mg in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 2.5 times increased level of  26 Mg is detected in the blood sample or tissue sample of the patient compared to a normal standard for  26 Mg. 
     
     
         6 . The method according to  claim 3 , wherein the method comprises measuring the level of  29 Si or  30 Si in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 2.4 times increased level of  29 Si or  30 Si is detected in the blood sample or tissue sample of the patient compared to a normal standard for  29 Si or  30 Si. 
     
     
         7 . The method according to  claim 3 , wherein the method comprises measuring the level of  57 Fe or  58 Fe in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 1.6 times increased level of  57 Fe or  58 Fe is detected in the blood sample or tissue sample of the patient compared to a normal standard for  57 Fe or  88 Fe. 
     
     
         8 . The method according to  claim 3 , wherein the method comprises measuring the level of at least one of the calcium isotopes  42 Ca,  43 Ca,  44 Ca,  46 Ca and  48 Ca in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 2.8 times increased level of at least one of the calcium isotopes  42 Ca,  43 Ca,  44 Ca,  46 Ca and  48 Ca is detected in the blood sample or tissue sample of the patient compared to a normal standard for the at least one of the calcium isotopes 42Ca,  43 Ca,  44 Ca,  46 Ca, and  48 Ca. 
     
     
         9 . The method according to  claim 2 , wherein the method further comprises measuring the level of at least one from the group consisting of sulfur isotopes, magnesium isotopes, silicon isotopes, calcium isotopes and iron isotopes in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if an increased level of at least one from the group consisting of sulfur isotopes, magnesium isotopes, silicon isotopes, calcium isotopes and iron isotopes is detected in the blood sample or tissue sample of the patient compared to a normal standard for the isotope. 
     
     
         10 . The method according to  claim 1 , wherein the levels of deuterium  2 D and  18 O are measured and diagnosing cancer in the patient if the levels of the  2 D and  18 O isotope are greater than the level of a normal standard for the  2 D and  18 O isotope.

Join the waitlist — get patent alerts

Track US2014255982A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.